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SCENARIO
In clinical trials, continuous outcomes,
such as intraocular pressure and visual
acuity, are often measured both before
treatment (ie, at baseline) and after treat-
ment. Having the baseline measurement
allows us to account for the initial differ-
ences between patients, which may well
have arisen by chance, when comparing
the outcomes of alternative treatments.
While randomisation provides a good
basis for comparisons between treatments
and lowers the probability of baseline
imbalance, imbalances can occur simply
due to the play of chance, particularly
when modest numbers of patients are
randomised.
Whether or not baseline measurements
are accounted for in the analysis may have
an impact on the results of a trial. Imagine a
randomised controlled trial with partici-
pants randomised to receive either treat-
ment A or treatment B. The primary
outcome for the trial is Best Corrected
Visual Acuity (BCVA) in the eye with the
poorer vision at recruitment, as measured
by the number of letters read on an Early
Treatment for Diabetic Retinopathy Study
EDTRS chart at a distance of 4 m. For the
purpose of this scenario, we are assuming
that only data from this eye contributes to
the analysis. The mean BCVA after treat-
ment is higher in the group allocated treat-
ment B than the group allocated treatment
A. However, by chance, the mean BCVA
before the start of treatment was also
higher for those allocated treatment
B. Therefore, although the mean values
after treatment suggest that treatment B is
better, there may have been as much, or
indeed more, improvement with treatment
A. This is something that needs to be con-
sidered when deciding how the data will be
analysed. Decisions about how the data will
be analysed should be made before looking
at the data (so that they are not inﬂuenced
by the results) and documented in a
Statistical Analysis Plan.1
This leaves us with the question: what
is the preferred way to analyse data of this
nature?
METHODS OF ANALYSIS
There are three common approaches to
the analysis of clinical trial data when we
have both baseline and post-treatment
values, namely:
1. Using a linear regression model, ﬁtting
baseline measurement as a patient-
level explanatory variable. This
method of analysis is known as ana-
lysis of covariance (ANCOVA).
2. Analysing post-treatment values only
(ie, ignoring baseline measurements).
3. Analysing change scores (ie, the differ-
ence between the post-treatment meas-
urement and baseline measurement for
each participant).
The merits of ANCOVA and its advan-
tages over the other two approaches are dis-
cussed in detail by Vickers and Altman.2
Brieﬂy, they conclude that ANCOVA is pref-
erable because it (1) provides an estimate of
the treatment effect (difference in mean
BCVA between treatments A and B) that is
unaffected by any baseline imbalance that
may exist between the treatment groups, and
(2) has a greater chance of detecting a treat-
ment difference if it exists (ie, is a more efﬁ-
cient approach than the other two methods).
Other statistical literature reinforces this gain
in efﬁciency and increase in power.3 4
When carrying out ANCOVA, a regres-
sion model is ﬁtted to the data of the form:
post-treatmentmeasurement
¼ aþ b1  treatment Bþ b2
 baselinemeasurementþ e
ð1Þ
The variable ‘treatment B’ takes the value
of 0 if the participant was allocated treat-
ment A, and 1 if the participant was allo-
cated treatment B. Using a statistical
package, we can obtain estimates of a, b1,
b2 and e. The estimate a is a constant, and
b1 quantiﬁes the size of the treatment effect
(ie, the mean difference between treatments
A and B). The baseline measurement is
termed a covariate, and e is an error term.
The value of the estimate b1 depends on
the baseline measurements (and the coefﬁ-
cient b2), and hence we say that our esti-
mate, b1, ‘is conditional upon’ (or less
formally ‘has been adjusted for’) the base-
line values.
The post-treatment measurements or
change scores (methods (2) and (3))
would typically be compared using a two-
sample t test. Taking the post-treatment
measurements as an example, it can be
shown that a two-sample t test is equiva-
lent to ﬁtting a regression model of the
form:
post-treatmentmeasurement
¼ aþ b1  treatment Bþ e
ð2Þ
The estimate, b1, corresponds to the dif-
ference in mean BCVA after treatment
between the groups. The baseline meas-
urement is not included, which is equiva-
lent to setting the estimate b2 in model (1)
to zero.
Looking then at change scores, the
model would be:
post-treatmentmeasurement
 baselinemeasurement
¼ aþ b1  treatment Bþ e
ð3Þ
An analysis of change scores is equivalent
to setting the estimate b2 in model (1) to 1.
EXAMPLE
Data from the Inhibition of VEGF in
Age-related choroidal Neovascularisation
(IVAN) randomised controlled trial com-
paring ranibizumab (Lucentis) and bevaci-
zumab (Avastin) for the treatment of
age-related choroidal neovascularisation5
have been analysed using the three
approaches outlined above to illustrate the
differences between the methods. The
mean BCVA in the study eye at baseline
and at the end of the study (24 months),
by drug, is shown in table 1. The mean
BCVA at 24 months was slightly higher in
the ranibizumab group. However, by
chance, this was accompanied by a slightly
higher mean baseline BCVA. The results
from each analysis are shown in table 2
and discussed below.
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Analysing post-treatment values only
(method 2, model 2)
Looking at post-treatment values only, we
do not take into account the higher base-
line values in the ranibizumab group, and
we therefore potentially overestimate the
differences between the treatments (or
had the chance imbalance been in the
opposite direction, we would potentially
underestimate the differences). From the
results of this analysis, we would say that
at the end of the trial, the average BCVA
was 1.7 letters higher in the ranibizumab
group compared with the bevacizumab
group. The 95% CI tells us that we are
95% conﬁdent that the difference in
mean BCVA is somewhere between 4.8
letters in favour of ranibizumab and 1.4
letters in favour of bevacizumab. As this
CI includes zero, we would not infer a
statistically signiﬁcant difference in mean
BCVA at the end of the trial between the
two drugs.
Analysing change scores (method 3,
model 3)
The analysis of change scores provides us
with an estimate of the difference in the
mean change from baseline between the
two treatment groups. Here, we are
taking account of how good the vision
was at the start of the trial (through the
calculation of the change score), but not
of differences in starting BCVA between
the two groups. From the results, we ﬁnd
that the mean increase in BCVA was 0.8
letters larger in the ranibizumab group,
with a 95% CI from 3.3 letters in favour
of ranibizumab to 1.6 letters in favour of
bevacizumab. Again, the CI includes zero,
so a difference between the groups is not
indicated.
Analysing post-treatment values with
baseline value as a covariate (ANCOVA,
method 1, model 1)
This is the preferred method of analysis.
Here, we are estimating the difference in
the mean BCVA between the two groups,
again taking account of how good the par-
ticipant’s vision was at the start of the
trial, but relaxing the restriction on the
relationship between baseline and post-
treatment measurements. From the
results, we would conclude that BCVA
improved by an estimated 1.1 letters
more, on average, in the ranibizumab
group than in the bevacizumab group,
with a 95% CI from 3.4 letters in favour
of ranibizumab to 1.3 letters in favour of
bevacizumab. As with the other two
models, there is no suggestion of a differ-
ence between the groups because the CI
includes zero. The estimated relationship
between the baseline and post-treatment
measurements for each drug is illustrated
in ﬁgure 1. The mean difference between
the two drugs (1.1 letters) is the vertical
distance between the two parallel lines.
DISCUSSION
In this example, all three methods led to
the same conclusion, namely that mean
BCVA at 24 months was similar between
the two drugs. However, the change score
analysis which made use of both baseline
and post-treatment measurements gave
more precise estimates (as shown by
smaller SE and narrower CI) than the ana-
lysis which just considered the post-
treatment measures. Further efﬁciency was
then gained using the more ﬂexible
ANCOVA model compared to the analysis
of change scores (SE 1.21 vs 1.25 letters,
95% CI (−3.4 to 1.3) vs (−3.3 to 1.6)).
While in this example all three methods
led to the same conclusion, it is possible
for different models to yield estimates that
might lead to different conclusions. If, for
example, the more precise estimate had
had a CI which excluded zero, while the
less precise estimates did not, we might
infer evidence of a treatment effect from
one model only. Some statisticians feel so
strongly about the use of ANCOVA that
they describe other methods as a hallmark
of second-rate analysis!6
Another approach to the analysis which
we would not recommend is to analyse
the difference between baseline and post-
treatment measurements in the two
groups separately, using two paired t tests.
This would test the hypothesis that the
change from baseline is zero separately for
each treatment group. The estimates
obtained would give the mean change
from baseline in each group, with a corre-
sponding 95% CI, but we would not be
able to draw a conclusion about, or quan-
tify the difference between, the two
drugs. If we were to perform two paired t
tests on our data, we would conclude that
there was a signiﬁcant improvement in
BCVA with both ranibizumab and bevaci-
zumab, with a mean improvement of 4.9
letters (95% CI 3.1 to 6.7) and 4.1 letters
(95% CI 2.4 to 5.8), respectively.
Performing separate analyses within each
treatment group is misleading, and either
an analysis of change scores or ANCOVA
are preferable.7
An additional consideration that has
not been explored here is how to handle
missing data. The methods described
would exclude any participant with
missing data for any of the measurements
included in the analysis. While every
effort should be made to prevent missing
Table 1 Mean values at baseline and post-treatment (24 months) (number of letters on
ETDRS chart)
Variable
Ranibizumab (n=268)
mean (SD)
Bevacizumab (n=249)
mean (SD)
BCVA at baseline 62.9 (14.6) 62.0 (15.3)
BCVA at 24 months 67.8 (17.0) 66.1 (18.4)
Change from baseline 4.9 (15.0) 4.1 (13.5)
BCVA, Best Corrected Visual Acuity.
Table 2 Analysis results
Model
Number of patients
included in the
analysis*
Treatment
difference†‡ 95% CI SE
Number of ETDRS letters
Method (2), model 2: Post-treatment
values only
517 −1.7 (−4.8 to 1.4) 1.55
Method (3), model 3: Change from
baseline
517 −0.8 (−3.3 to 1.6) 1.25
Method (1), model 1: Post-treatment
values with baseline value as a
covariate
517 −1.1 (−3.4 to 1.3) 1.21
*Although 525 patients reached the 24-month visit in the IVAN trial, BCVA data are missing for 8 of these patients.
†Difference in mean BCVA (bevacizumab—ranibizumab).
‡The results presented differ from the published results.5 For illustrative purposes, only the drug treatment was included
in the model; BCVA measured during follow-up and other factors included models used to obtain the published results
have not been included.
BCVA, Best Corrected Visual Acuity.
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data by study design and management,
missing values can and do occur. For
example, in the IVAN trial, participants
underwent optical coherence tomography
to assess retinal thickness and other lesion
morphology, but on occasions, the
machine was not working and the mea-
surements were not taken. There are dif-
ferent ways in which missing data can be
handled and you should consult a statisti-
cian on the best way to proceed.
Approaches include omitting the cases
with missing data, which is an inefﬁcient
use of the data, reducing precision and
power; imputing the missing values,
which must be done with care8; and
ﬁtting a more sophisticated model where
the baseline and post-treatment measure-
ments are modelled ‘jointly’, which allows
participants with partial missing data to
be included.9 However, it is very import-
ant to remember that none of these
methods are a solution to missing data,
and that every effort should be made to
prevent it.
In summary, while there are different
methods available for analysing trial data
with baseline and post-treatment measure-
ments, the recommended approach is
ANCOVA for the reasons outlined. The
choice of analysis method can impact the
results of a trial, and therefore, it is
important to choose the most appropriate
method in advance to ensure precise and
unbiased conclusions.
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Figure 1 Baseline and
post-treatment Best Corrected Visual
Acuity (BCVA) for the subset of
patients with a post-treatment BCVA of
more than 50 letters (n=425 patients).
The estimated difference in mean
BCVA between the two drugs groups
from the analysis of covariance is the
vertical distance between the two
regression lines shown on the plot.
Open Access
Scan to access more
free content
Nash R, et al. Br J Ophthalmol November 2014 Vol 98 No 11 1469
Editorial
